Article

Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii Strains Isolated at the German Military Field Laboratory in Mazar-e Sharif, Afghanistan

Paul G. Higgins†,‡, Meret Kniel†, Sandra Rojak³, Carsten Balczun³, Holger Rohde⁴, Hagen Frickmann⁵,⁶‡, and Ralf Matthias Hagen³,*

1 Institute for Medical Microbiology, Immunology, and Hygiene, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50935 Cologne, Germany; paul.higgins@uni-koeln.de
2 German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, 50935 Cologne, Germany
3 Department of Microbiology and Hospital Hygiene, Bundeswehr Central Hospital Koblenz, 56070 Koblenz, Germany; meret.kniel@web.de (M.K.); sandrarojak@bundeswehr.org (S.R.); carsten1balczun@bundeswehr.org (C.B.)
4 Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany; rohde@uke.de
5 Department of Microbiology and Hospital Hygiene, Bundeswehr Hospital Hamburg, 20359 Hamburg, Germany; frickmann@bnitm.de or hagen.frickmann@med.uni-rostock.de
6 Institute for Medical Microbiology, Virology and Hygiene, University Medicine Rostock, 18057 Rostock, Germany
* Correspondence: ralfmatthiashagen@bundeswehr.org; Tel.: +49-261-896-77200
† Paul G. Higgins and Meret Kniel equally contributed to this work.
‡ Hagen Frickmann and Ralf Matthias Hagen equally contributed to this work.

Abstract: The study was performed to provide an overview of the molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Afghanistan isolated by the German military medical service during the Afghanistan conflict. A total of 18 isolates were collected between 2012 and 2018 at the microbiological laboratory of the field hospital in Camp Marmal near Mazar-e Sharif, Afghanistan, from Afghan patients. The isolates were subjected to phenotypic and genotypic differentiation and antimicrobial susceptibility testing as well as to a core genome multi-locus sequence typing (cgMLST) approach based on whole-genome next-generation sequence (wgNGS) data. Next to several sporadic isolates, four transmission clusters comprising strains from the international clonal lineages IC1, IC2, and IC9 were identified. Acquired carbapenem resistance was due to \( \text{bla}_{\text{OXA-23}} \) in 17/18 isolates, while genes mediating resistance against sulfonamides, macrolides, tetracyclines, and aminoglycosides were frequently identified as well. In conclusion, the assessment confirmed both the frequent occurrence of \( A. \text{baumannii} \) associated with outbreak events and a variety of different clones in Afghanistan. The fact that acquired carbapenem resistance was almost exclusively associated with \( \text{bla}_{\text{OXA-23}} \) may facilitate molecular resistance screening based on rapid molecular assays targeting this resistance determinant.

Keywords: Acinetobacter baumannii; molecular epidemiology; carbapenem resistance; Afghanistan; surveillance

1. Introduction

Carbapenem-resistant Acinetobacter baumannii has been identified as a considerable menace for traumatic wounds associated with international wars and crises [1,2]. This also applies to the recent military conflict in Afghanistan, in which German soldiers participated for nearly 20 years, from 2002 until 2021.

Most reports on war trauma-associated \( A. \text{baumannii} \) infections or colonization from the recent Afghanistan conflict were, however, provided by the medical services of the
USA and Canada [3–11]. As early as 2004, a report on a limited number of A. baumannii-associated bloodstream infections associated with Operation Enduring Freedom (OEF) in Afghanistan was published [3]. In 2006, carbapenem-resistant isolates were still reported to be acquired predominantly in Iraq and less frequently in Afghanistan [4]. One year later, however, Canadian health officials published warnings about the risk of spreading multidrug-resistant A. baumannii strains imported into Canadian hospitals from Afghan battlefields [5]. Subsequently, in 2008, the US Armed Forces Medical Service reported an increased frequency of A. baumannii isolates associated with osteomyelitis in war-injured soldiers fighting for the OEF mission [6], and in the same year, an increased acquisition risk of resistant A. baumannii isolates at OEF deployment sites was documented [7]. Together with Staphylococcus aureus and Klebsiella pneumoniae, A. baumannii accounted for nosocomial infection rates of 2–4% in injured patients from the OEF mission [8], and a risk of spreading resistance was identified. However, as reported in 2011, the colonization rate with A. baumannii was highest at the beginning of the mission and declined in the following years [9]. Nevertheless, the relevance of resistant or even multidrug-resistant A. baumannii strains in the wounds of war-injured US trauma patients remained considerable, accounting for 38.6% of the registered infections due to multidrug-resistant Gram-negative bacteria [10]. In a recent study on trauma-related infections in US soldiers, Acinetobacter spp. were isolated from 8.7% of skin and soft tissue infections, 9.0% of bloodstream infections, and 11.0% of osteomyelitis cases, [11]. Consequently, research on substances potentially inactivating A. baumannii in traumatic war injuries is ongoing [12].

German soldiers in Afghanistan were affected by multidrug-resistant A. baumannii as well, but the documentation is considerably less comprehensive. In 2011, Vandersee and colleagues [13] started reporting antimicrobial resistance issues associated with bacterial pathogens isolated from deployed German soldiers as well as from local allies in Afghanistan, which was later confirmed by Helm in 2013 [14].

Unfortunately, however, little published information is available on the molecular epidemiology of Afghan A. baumannii isolates or their antibiotic resistance determinants, although respective typing efforts have been described since 2006 [4]. In the meantime, 27,000 bacterial strains have been sequenced in the course of the Antimicrobial Resistance Monitoring and Research (ARMoR) program at the Walter Reed Army Institute of Research (Silver Spring, MD, USA) [15]. Nevertheless, available information remains scarce. In a recent Swedish assessment, the predominance of A. baumannii international clone 1 (IC1) was reported for Afghanistan, with IC1 lineage 3 being virtually limited to Afghanistan, Pakistan, and India [16]. In a recent small study [17], four carbapenem-resistant A. baumannii were included, which were isolated in the course of a minor outbreak in a German field hospital in northern Afghanistan in 2008; shipped to the US Regional Medical Center Landstuhl (RMCL), Germany; and donated by RMCL to the Bundeswehr Hospital Hamburg, Germany, for a study on fluorescence-in-situ-hybridization (FISH)-based identification of Acinetobacter spp. in 2011 [18]. Those four A. baumannii strains were identified as international clone 1 (IC1), Oxford sequence type (ST) 498, and Pasteur ST 81 [19–21] and carried the beta-lactamase genes bla_{ADC-25-like}, bla_{OXA-23}, and bla_{OXA-69}, as well as the genes aadB-like, aph(3’)-Ia, and aph(3’)-V1a-like, mediating aminoglycoside resistance, next to sul-2 which mediates sulphonamide resistance [17].

Beginning in 2012, multidrug-resistant bacterial strains isolated at the microbiological laboratory of the German military field hospital in Camp Marmal near Mazar-e-Sharif, Afghanistan, were sent to the laboratory at the Bundeswehr Central Hospital in Koblenz, Germany. Within a period of 6 years from 2012 to 2018, a total of 18 carbapenem-resistant A. baumannii strains isolated from Afghan patients were shipped from Mazar-e-Sharif, Afghanistan, to Koblenz, Germany. In the study presented here, those strains were assessed by whole-genome next-generation sequencing (wgNGS) for clonal relationship testing, and phenotypic resistance testing was compared to identify genetic resistance determinants. By doing so, the study intended to contribute to the so-far scarcely available knowledge on the local epidemiology of carbapenem-resistant A. baumannii in Afghanistan.
2. Materials and Methods

2.1. Strains

A total of 18 carbapenem-resistant *Acinetobacter baumannii* strains were isolated from both clinical and screening samples of Afghan patients (n = 18) at the microbiological laboratory of the German military field hospital at Camp Marmal near Mazar-e Sharif, Afghanistan, between the years 2012 and 2018. After isolation, the strains were transferred to the microbiological laboratory of the Bundeswehr Central Hospital in Koblenz, Germany, for confirmatory testing as well as surveillance purposes. To ensure the patients’ anonymity, patient-specific details are not provided in agreement with the ethical clearance for this study.

2.2. Phenotypic Assessments

At the Bundeswehr Central Hospital in Koblenz, Germany, a preliminary confirmation of the species identities at the *A. baumannii* complex level was performed by matrix-assisted laser-desorption-ionization time-of-flight mass spectrometry (MALDI TOF MS) using a Bruker MALDI Biotyper™ MBT™ smart mass spectrometer and the software MBT compass version 4.1. Antimicrobial resistance was assessed using N 248-cards of a VITEK-II automate (BioMérieux, Marcy-l’Etoile, France). Because of the known problem of poor reliability of VITEK-II-based colistin resistance testing [22], the microbroth dilution assay MICRONAUT-S (MERLIN Diagnostika GmbH, Bornheim, Germany) was applied for this purpose. Phenotypic resistance testing results were interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards version 11.0.

2.3. Genotypic Assessments

From all assessed strains, total DNA was extracted using the DNeasy Ultra Clean Microbial Kit (Qiagen, Hilden, Germany) as suggested by the manufacturer and shipped to the Institute for Medical Microbiology, Immunology, and Hygiene of the University of Cologne, Germany, for further molecular assessments. In detail, the species-identity of the *A. baumannii* strains was confirmed by *gyrB* multiplex PCR [23,24]. Additional screening PCRs [25,26] targeting common beta-lactamases were applied. In addition, whole-genome sequencing from the extracted nucleic acids of the strains was performed as previously described with minor modifications [17,27]. Briefly, sequencing libraries were prepared with the purified DNA using the Ultra II FS DNA Library Prep Kit (New England Biolabs, Frankfurt, Germany) for 250 bp paired-end sequencing runs on an Illumina MiSeq sequencer. Subsequently, the Velvet assembler integrated with the Ridom SeqSphere+ v.7.2.3 software performed de novo assembling of the obtained reads. Project-associated raw sequencing reads were submitted to the European Nucleotide Archive (https://www.ebi.ac.uk/ena/ (accessed on 22 October 2021)) with the accession number PRJEB47537. The sequences were subjected to a validated core genome multi-locus sequence typing (cgMLST) scheme [28] using the Ridom SeqSphere+ v. 7.2.3 software (Ridom GmbH, Münster, Germany). By generating a minimum spanning tree including 2390 target alleles using the same software tool, also including an in-house library with the established international clones, the clonal relationship between the isolates was visualized. In addition, the genome assemblies of all isolates were used to identify sequence types (STs) according to the Oxford and the Pasteur 7-loci MLST schemes [19–21], as shown on the pubMLST website (https://pubmlst.org/abaumannii/ (accessed on 22 October 2021)). The acquired resistome was identified using the webtool ResFinder 2.1 (http://www.bldb.eu/ (accessed on 22 October 2021)) (batch upload), and *blaOXA* genes were identified using the BLAST function of the beta-lactamase database (http://www.bldb.eu/ (accessed on 22 October 2021)) [29,30].

2.4. Ethical Clearance

Ethical clearance for the anonymized retrospective assessment of the strains without the requirement of informed consent was obtained from the ethics committee of the medical
association of Rheinland-Pfalz (reference number 2021-16003, provided on 30 July 2021). The study was conducted in line with the requirements of the Declaration of Helsinki.

3. Results
3.1. Phylogeny Based on Core Genome Sequence Typing

The cgMLST analysis indicated four transmission clusters, comprising six, four, two, and two isolates, respectively (Figure 1). Three out of those four transmission clusters could be attributed to the international clones (IC) IC1, IC2, and IC9, while the other cluster was genetically distinct from the international clonal lineages. The remaining four isolates were singletons, although three of them clustered within the international clonal lineages but without sufficient genomic similarity to suggest nosocomial transmission (Figure 1).

![Figure 1](attachment:image.png)

**Figure 1.** A minimum spanning tree of the *A. baumannii* strains based on 2390 target alleles (core genome) is presented. The study I.D.s of the isolates are shown within the nodes, and the numbers between the nodes indicate the number of alleles that were different. Isolates, which are elements of transmission clusters, are either shown within the same node or connected with transparent bands. Isolates are colored based on the detected *bla*OXA gene.

In addition, the sequence assemblies of all strains were subjected to seven-loci multilocus sequence typing (MLST) schemes, i.e., the Oxford scheme and the Pasteur scheme (Table 1) [19–21]. Isolates clustering with the ICs had the expected Pasteur STs. With one exception, IC1 and IC2 isolates had two Oxford STs owing to their double *gdhB* loci.
Table 1. Summary of the isolates from Afghan patients based on their clonal lineages, multi-locus sequence types, intrinsic and acquired beta-lactamases, and history of acquisition.

| Numeric I.D. | Clonal Lineage | Pasteur Sequence Type | Oxford Sequence Type | Acquired Beta-Lactamase | Intrinsic Beta-Lactamase | Year of Isolation | Anatomic Isolation Site |
|--------------|----------------|-----------------------|----------------------|-------------------------|-------------------------|-------------------|------------------------|
| 339787       | IC1            | 94                    | 1812/1813            | blaoxa-23               | blaoxa-49               | 2013              | Lung                   |
| 343633       | IC1            | 94                    | 1812/1813            | blaoxa-23               | blaoxa-49               | 2013              | Bullet wound           |
| 343733       | IC1            | 94                    | 1812/1813            | blaoxa-23               | blaoxa-49               | 2013              | Broncho-alveolar lavage|
| 345288       | IC1            | 94                    | 1812/1813            | blaoxa-23               | blaoxa-49               | 2013              | Unknown *              |
| 367504       | IC1            | 94                    | 1812/1813            | blaoxa-23               | blaoxa-49               | 2014              | Rectum                 |
| 367492       | IC1            | 94                    | 1812/1814            | blaoxa-23               | blaoxa-49               | 2014              | Nose                   |
| 334424       | IC1            | 325                   | blaoxa-23            | 387                     | blaoxa-49               | 2013              | Groin                  |
| 363954       | IC2            | 2                     | 1114/1841            | blaoxa-23               | 387                     | 2014              | Tracheal secretion     |
| 365401       | IC2            | 2                     | 1114/1841            | blaoxa-23               | 387                     | 2014              | Nose                   |
| 334432       | IC7            | 25                    | 2280                 | blaoxa-23               | 387                     | 2013              | Leg wound              |
| 365526       | IC8            | 10                    | 447                  | blaoxa-58               | 387                     | 2018              | Blood culture           |
| 313803       | IC9            | 85                    | 1752                 | blaoxa-94               | 387                     | 2012              | Unknown *              |
| 314287       | IC9            | 85                    | 1752                 | blaoxa-94               | 387                     | 2012              | Unknown *              |
| 337300       | no             | 136                   | new                  | blaoxa-23               | 387                     | 2013              | Bullet wound (knee)    |
| 341183       | no             | 136                   | new                  | blaoxa-23               | 387                     | 2013              | Thoracic wound         |
| 341027       | no             | 136                   | new                  | blaoxa-317              | 387                     | 2013              | Blood culture           |
| 344173       | no             | 136                   | new                  | blaoxa-317              | 387                     | 2013              | Unknown *              |
| 390268       | no             | 52                    | 931                  | blaoxa-51               | 387                     | 2015              | Unknown *              |

* Unknown = insufficient data available. I.D. = identity.

3.2. Genotypic and Phenotypic Resistance

Genotypic resistance testing identified multiple genetic determinants. In all isolates, carbapenem-resistance was associated with an acquired OXA-type gene, with blaoxa-23 found in all except one isolate, which had blaoxa-58. One isolate had an additional blaces-11. All isolates possessed the intrinsic blaad (not shown in Table 2 below) and blaoxa-51-like with variants associated with the international clones. Multiple acquired aminoglycoside modifying enzymes were associated with aminoglycoside resistance, comprising aadB-like, aac(3)-la-like, aacA4-like, aadA1, aph(3′)-lc, aph(3′)-lc-like, aac(3)-IId-like, aph(3′)-Vla-like, armA, strA, and strB (Table 2). High gentamicin minimum inhibitory concentrations (MICs) were associated with aadB-like, while amikacin resistance was associated with armA in one isolate and aph(3′)-Vla in ten isolates. However, two isolates with this gene were amikacin-susceptible. The element aac(6′)Ib-cr-like identified in one strain is linked to combined aminoglycoside and fluoroquinolone resistance. However, fluoroquinolone resistance was associated with target-site mutations in the gyrA and parC genes. Further, the tet-gene variants tet(39), tet(B), and tet(B)-like, mediating tetracycline resistance; sulI and sul2, mediating sulfonamide resistance; and mph(E) and msr(E), mediating macrolide resistance, were among the more frequently observed resistance determinants. By contrast, ARR-2, mediating rifampicin resistance; cmlA1-like, mediating phenicole resistance; and dfrA7, mediating trimethoprim resistance, were only recorded once each. Details are provided in Table 2, and the corresponding phenotypic resistance details are summarized in Table 3 below.

Table 2. Antimicrobial resistance determinants as identified within the A. baumannii strains.

| Numeric I.D. | Beta-Lactamase Genes | Aminoglycoside Resistance Genes | Sulfonamide Resistance Genes | Macrolide Resistance Genes | Tetracycline Resistance Genes | Other Rarely Observed Resistance Genes |
|--------------|-----------------------|--------------------------------|-----------------------------|---------------------------|-------------------------------|---------------------------------------|
| 339787       | blaoxa-23, blaoxa-49   | aadB-like, aph(3′)-lc-like     | sul2                        | mph(E), msr(E)            |                               |                                       |
| 343633       | blaoxa-23, blaoxa-49   | aadB-like                       | sul2                        | mph(E), msr(E)            |                               |                                       |
| 343733       | blaoxa-23, blaoxa-49   | aadB-like, aph(3′)-lc           | sul2                        | mph(E), msr(E)            |                               |                                       |
| 345288       | blaoxa-23, blaoxa-49   | aadB-like, aph(3′)-lc           | sul2                        | mph(E), msr(E)            |                               |                                       |
| 367504       | blaoxa-23, blaoxa-49   | aadB-like, aph(3′)-lc           | sul2                        | mph(E), msr(E)            |                               |                                       |
### Table 2. Cont.

| Numeric I.D. | Beta-Lactamase Genes | Aminoglycoside Resistance Genes | Sulfonamide Resistance Genes | Macrolide Resistance Genes | Tetracycline Resistance Genes | Other RarelyObserved Resistance Genes |
|--------------|-----------------------|--------------------------------|-----------------------------|-----------------------------|--------------------------------|-------------------------------------|
| 367492       | **bla**<sub>OXA-23</sub>, **bla**<sub>OX-48</sub> | **aadA**-like, **aph(3')-Ic**, **aph(3')-Vla-like** | sul2                        | mph(E), msr(E)             |                                |                                     |
| 334424       | **bla**<sub>OXA-23</sub>, **bla**<sub>OX-48</sub> | **aadA**-like, **aph(3')-Vla-like** | sul2                        | mph(E), msr(E)             |                                |                                     |
| 369354       | **bla**<sub>OXA-23</sub>, **bla**<sub>OX-48</sub> | **aac(3)-Ia-like, andA1, strA, strB** | sul1, sul2                 |                                | tet(B)-like                      |                                     |
| 365401       | **bla**<sub>OXA-23</sub>, **bla**<sub>OX-48</sub> | **aac(3)-Ia-like, andA1, strA, strB** | sul1, sul2                 |                                | tet(B)-like                      |                                     |
| 334432       | **bla**<sub>OXA-23</sub>, **bla**<sub>OX-48</sub>, **MBE-87** | **armA**, strA, strB | sul1, sul2                 | mph(E), msr(E)             |                                | ARR-2*, cmr(A1)-like**                  |
| 365526       | **bla**<sub>CMY-1</sub>, **apr**<sub>ESBL</sub> | **aadA**-like, **aph(3')-Vla-like, strA, strB** | sul2                        | mph(E), msr(E)             |                                |                                     |
| 313803       | **bla**<sub>OXA-23</sub>, **bla**<sub>OX-48</sub> | **aadA**-like, **aph(3')-Vla-like** | sul2                        | mph(E), msr(E)             |                                |                                     |
| 314287       | **bla**<sub>OXA-23</sub>, **bla**<sub>OX-48</sub> | **aadA**-like, **aph(3')-Vla-like** | sul2                        | mph(E), msr(E)             |                                |                                     |
| 327300       | **bla**<sub>OXA-23</sub>, **bla**<sub>OX-317</sub> | **aadA**-like, **aph(3')-Vla-like, strA, strB** | sul2                        |                                | tet(39)  |                                     |
| 341183       | **bla**<sub>OXA-23</sub>, **bla**<sub>OX-317</sub> | **aadA**-like, **aph(3')-Vla-like, strA, strB** | sul2                        |                                | tet(39)  |                                     |
| 341027       | **bla**<sub>OXA-23</sub>, **bla**<sub>OX-317</sub> | **aadA**-like, **aph(3')-Vla-like, strA, strB** | sul2                        |                                | tet(39)  |                                     |
| 344173       | **bla**<sub>OXA-23</sub>, **bla**<sub>OX-317</sub> | **aadA**-like, **aph(3')-Vla-like, strA, strB** | sul2                        |                                | tet(39)  |                                     |
| 390268       | **bla**<sub>GES-1</sub>, **bla**<sub>OXA-23</sub>, **bla**<sub>OX-31</sub> | **aph(3')-Vla-like, aceA4-like** | sul1, sul2                 |                                | tet(B)   | dfra7***, aac(6')-Ib-cr-like**** |

* mediating rifampicin resistance. ** mediating phenicol resistance. *** mediating trimethoprim resistance. **** mediating combined fluoroquinolone and aminoglycoside resistance. † intrinsic **bla**<sub>OXA-51</sub> variant.

### Table 3.

Phenotypic resistance testing results based on microbroth dilution (applied for colistin) and automated resistance testing using a VITEK-II device (applied for all other assessed antimicrobial substances). MICs (minimum inhibitory concentrations in µg/mL) are shown in brackets. Interpretation was performed according to the EUCAST NAK (European Committee on Antimicrobial Susceptibility Testing, "Nationales Antibiotikasensitivitätstest-Komitee"). S = susceptible. I = Susceptible at increased dosage. R = Resistant.

| Numeric I.D. | Imipenem | Meropenem | Amikacin | Gentamicin | Tobramycin | Ciprofloxacin | Cotrimoxazole | Colistin |
|--------------|----------|-----------|----------|------------|------------|---------------|---------------|----------|
| 339787       | R (8)    | I (8)     | S (4)    | R (≥16)    | R (≥16)    | R (≥320)      | S (0.25)      |         |
| 343633       | R (8)    | R (≥16)   | S (≥2)   | R (≥16)    | R (≥8)     | R (≥320)      | S (0.5)       |         |
| 343733       | R (8)    | R (≥16)   | S (4)    | R (≥16)    | R (≥8)     | R (≥320)      | S (0.5)       |         |
| 345288       | R (8)    | R (≥6)    | S (4)    | R (≥16)    | R (16)     | R (≥320)      | S (0.25)      |         |
| 367904       | R (≥16)  | R (≥16)   | S (4)    | R (≥16)    | R (≥16)    | R (≥320)      | S (0.25)      |         |
| 367492       | R (8)    | R (≥16)   | S (≥2)   | R (≥16)    | R (≥8)     | R (≥320)      | S (0.5)       |         |
| 334424       | R (8)    | I (8)     | R (16)   | R (≥16)    | R (8)      | R (≥320)      | S (0.25)      |         |
| 369354       | R (≥16)  | R (≥16)   | S (≥2)   | R (8)      | S (≤1)     | R (≥320)      | S (0.5)       |         |
| 365401       | R (≥16)  | R (≥16)   | R (≥64)  | R (≥8)     | R (≥16)    | R (≥320)      | S (0.5)       |         |
| 334432       | R (≥16)  | R (≥16)   | R (≥64)  | R (8)      | R (≥16)    | R (≥320)      | S (0.5)       |         |
| 365526       | R (≥16)  | R (≥16)   | R (≥64)  | R (8)      | R (≥8)     | R (≥320)      | S (0.5)       |         |
| 313803       | R (≥16)  | R (≥16)   | R (≥16)  | R (≥16)    | R (≥8)     | R (≥320)      | S (0.25)      |         |
| 314287       | R (≥16)  | R (≥16)   | R (≥16)  | R (≥8)     | R (≥8)     | R (≥320)      | S (0.5)       |         |
| 337380       | R (≥16)  | R (≥16)   | R (≥64)  | R (8)      | R (≥8)     | R (≥320)      | S (0.5)       |         |
| 341163       | R (≥16)  | I (8)     | R (≥64)  | R (≥16)    | R (≥16)    | R (≥320)      | S (0.5)       |         |
| 341027       | R (≥16)  | R (≥16)   | R (≥64)  | R (≥16)    | R (≥16)    | R (≥320)      | S (0.5)       |         |
| 344173       | R (≥16)  | R (≥16)   | R (≥64)  | R (≥16)    | R (≥16)    | R (≥320)      | S (0.5)       |         |
| 390268       | R (≥16)  | R (≥16)   | R (≥64)  | R (8)      | R (8)      | R (≥320)      | S (1.0)       |         |

### 4. Discussion

This study was performed to provide information on the molecular epidemiology of carbapenem-resistant <i>A. baumannii</i> strains collected from patients in Afghanistan by
deployed soldiers of the German military medical service in the course of the recent conflict in Afghanistan. The assessment identified strains that clustered with the international clonal lineages IC1, IC2, and IC9 next to several singletons. The regional detection of IC1 strains aligns well with previous reports [16,17], while IC2 was recently reported to be prevalent in civil war-injured Syrian patients [17]. The MLST types observed for the IC1 isolates, however, were different from the previously reported ones [17], and the cgMLST analysis indicated a distance of 619 alleles between the IC1 cluster from the previous assessment [17] and the present one. Therefore, the study suggests that even within IC1, considerable phylogenetic distance can be expected for *A. baumannii* clones prevalent in Afghanistan. By contrast, the IC2 isolates from this study were only 92 alleles distant from an IC2 isolate from Syria [17].

As four transmission clusters and only a few singletons were observed, this assessment confirms previous observations by the German military medical service that multidrug-resistant *A. baumannii* occurred predominantly associated with outbreak scenarios in Afghanistan in military medical infrastructure [13,14], while randomly isolated strains apart from outbreak events were quite rare. Unfortunately, the retrospective design of the study and the ethical need for anonymization prevented more detailed assessments of likely transmission chains.

In line with previous findings [17], carbapenem resistance was nearly exclusively associated with the abundance of the *bla*OXA-23 gene, while various genes mediating resistance against sulfonamides, macrolides, tetracyclines, and aminoglycosides were also identified. The nearly monogenetic association of carbapenem-resistance in the assessed Afghan *A. baumannii* isolates may be of practical interest if PCR-based screening based on automated point-of-care testing (POCT) assays for carbapenem-resistant *A. baumannii* in Afghan patients are considered for hygiene reasons or guidance of antimicrobial therapy [31].

Focusing on residual susceptibility toward other tested antibiotic drugs, ubiquitous susceptibility toward colistin could be demonstrated next to heterogeneous susceptibility toward the aminoglycosides amikacin and tobramycin. Despite the abundance of aminoglycoside modifying enzymes, with all but one isolate in possession of ≥2 resistance genes, two isolates were susceptible to tobramycin, and seven were susceptible to amikacin, while all were gentamicin-resistant. This highlights that it is not always possible to correlate phenotype with genotype and emphasizes that minimum inhibitory concentration (MIC) testing cannot easily be replaced by molecular resistance prediction. Furthermore, efflux can also contribute to aminoglycoside resistance in *A. baumannii*, but we did not investigate this in this study. Of note, tigecycline was not assessed, as susceptibility testing results were interpreted in line with EUCAST (European Committee on Antimicrobial Susceptibility Testing) standards, which do not describe breakpoints for tigecycline.

The study has a number of limitations. First, the available number of isolates was quite low, limiting the representativeness of the assessment. Second, and for the same reason, the anonymity of the patients demanded abstaining from a very detailed presentation of clinical information. In some cases, these data were also incompletely documented and thus only partly available. Third, the completeness of the collection is uncertain, as only isolates transferred from Afghanistan could be included in the sample collection in Koblenz. Accordingly, the results can only provide another piece in the puzzle of the molecular epidemiology of carbapenem-resistant *A. baumannii* strains in Afghanistan. Fourth, no long-read sequencing was performed in the course of the present study. Therefore, no information on the exact positions of insertion sequences in the bacterial genomes and thus on their functional relevance can be provided.

5. Conclusions

In spite of the above-mentioned limitations, the assessment provided a number of interesting insights. Therefore, the abundance of the international clonal lineages IC1, IC2, and IC9 of *A. baumannii* next to several out-standers could be confirmed for Afghanistan.
Further, it was shown that acquired carbapenem-resistance in the assessed Afghan *A. baumannii* strains was nearly exclusively due to *bla*\(_{OXA-23}\) genes, which may be a helpful hint for molecular diagnostic purposes.

**Author Contributions:** Conceptualization, H.F., H.R. and R.M.H.; methodology, P.G.H.; software, P.G.H.; validation, P.G.H.; formal analysis, P.G.H.; investigation, P.G.H., C.B., S.R. and M.K.; resources, R.M.H. and P.G.H.; data curation, P.G.H. and M.K.; writing—original draft preparation, M.K. and H.F.; writing—review and editing, P.G.H., H.F., S.R., H.R., C.B., M.K. and R.M.H.; visualization, P.G.H.; supervision, R.M.H.; project administration, R.M.H. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Ethical clearance for the anonymized retrospective assessment of the strains without the requirement of informed consent was obtained from the ethics committee of the medical association of Rheinland-Pfalz (reference number 2021-16003, provided on 30 July 2021). The study was conducted in line with the requirements of the Declaration of Helsinki.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All relevant data are provided in the manuscript or via the links provided in the manuscript. Raw data may be made accessible upon reasonable request.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Davis, K.A.; Moran, K.A.; McAllister, C.K.; Gray, P.J. Multidrug-resistant *Acinetobacter* extremity infections in soldiers. Emerg. Infect. Dis. 2005, 11, 1218–1224. [CrossRef] [PubMed]

2. O’Shea, M.K. *Acinetobacter* in modern warfare. Int. J. Antimicrob. Agents 2012, 39, 363–375. [CrossRef] [PubMed]

3. Centers for Disease Control and Prevention (CDC). *Acinetobacter baumannii* infections among patients at military medical facilities treating injured U.S. service members, 2002–2004. MMWR Morb. Mortal. Wkly. Rep. 2004, 53, 1063–1066.

4. Hujer, K.M.; Hujer, A.M.; Hulten, E.A.; Bajaksouzian, S.; Adams, J.M.; Donskey, C.J.; Ecker, D.J.; Massire, C.; Eshoo, M.W.; Sampath, R.; et al. Analysis of antibiotic resistance genes in multidrug-resistant *Acinetobacter* sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob. Agents Chemother. 2006, 50, 4114–4123. [CrossRef] [PubMed]

5. Stuart, T.L.; Mulvey, M.; Simor, A.E.; Tien, H.C.; Battad, A.; Taylor, G.; Vayalumkal, J.V.; Weir, C.; Ofner, M.; Gravel, D.; et al. *Acinetobacter baumannii* in casualties returning from Afghanistan. Can. J. Infect. Control 2007, 22, 152–154. [PubMed]

6. Yun, H.C.; Branstetter, J.G.; Murray, C.K. Osteomyelitis in military personnel wounded in Iraq and Afghanistan. J. Trauma 2008, 64 (Suppl. 2), S163–S168. [CrossRef]

7. Calhoun, J.H.; Murray, C.K.; Manring, M.M. Multidrug-resistant organisms in military wounds from Iraq and Afghanistan. Clin. Orthop. Relat. Res. 2008, 466, 1356–1362. [CrossRef] [PubMed]

8. Murray, C.K.; Yun, H.C.; Griffith, M.E.; Thompson, B.; Crouch, H.K.; Monson, L.S.; Aldous, W.K.; Mende, K.; Hospenthal, D.R. Recovery of multidrug-resistant bacterial flora from combat personnel evacuated from Iraq and Afghanistan at a single military treatment facility. Mil. Med. 2009, 174, 598–604. [CrossRef] [PubMed]

9. Hospenthal, D.R.; Crouch, H.K.; English, J.F.; Leach, F.; Pool, J.; Conger, N.G.; Whitman, T.J.; Wotrman, G.W.; Robertson, J.L.; Murray, C.K. Multidrug-resistant bacterial colonization of combat-injured personnel at admission to medical centers after evacuation from Afghanistan and Iraq. J. Trauma 2011, 71 (Suppl. 1), S52–S57. [CrossRef] [PubMed]

10. Campbell, W.R.; Li, P.; Whitman, T.J.; Blyth, D.M.; Schnaubelt, E.R.; Mende, K.; Tribble, D.R. Multi-Drug-Resistant Gram-Negative Infections in Deployment-Related Trauma Patients. Surg. Infect. 2017, 18, 357–367. [CrossRef] [PubMed]

11. Weintrob, A.C.; Murray, C.K.; Xu, J.; Krauss, M.; Bradley, W.; Warkentien, T.E.; Lloyd, B.A.; Tribble, D.R. Early Infections Complicating the Care of Combat Casualties from Iraq and Afghanistan. Surg. Infect. 2018, 19, 286–297. [CrossRef]

12. Bogue, A.L.; Panmanee, W.; McDaniel, C.T.; Mortensen, J.E.; Kamau, E.; Actis, L.A.; Johannigman, J.A.; Schurr, M.J.; Satish, L.; Kotagiri, N.; et al. AB569, a non-toxic combination of acidified nitrite and EDTA, is effective at killing the notorious *Iraq/Afghanistan combat wound pathogens*, multi-drug resistant *Acinetobacter baumannii* and *Acinetobacter* spp. *PLoS ONE* 2021, 16, e0247513. [CrossRef]

13. Vandersee, S.; Hannemann, M.; Herrmann, F.; Becker, P. Multiresistente Erreger bei Patienten des deutschen Bundeswehr-Einsatzlazaretts in Masar-e Sharif. *Hyg. Med.* 2011, 36, 384–392.

14. Helm, F. Einsatzsurveillance. ISAF und die Maxime des Inspektors. *Wehrmed. Wehrpharm.* 2013, 1, 40–45.

15. Lesho, E.; Clifford, R.; Ommus-Leone, F.; Appalla, L.; Snesrud, E.; Kwak, Y.; Ong, A.; Maybank, R.; Waterman, P.; Rohrbeck, P.; et al. The Challenges of Implementing Next Generation Sequencing Across a Large Healthcare System, and the Molecular Epidemiology
and Antibiotic Susceptibilities of Carbapenemase-Producing Bacteria in the Healthcare System of the U.S. Department of Defense. PLoS ONE 2016, 11, e0155770. [CrossRef]
16. Karah, N.; Wai, S.N.; Uhlin, B.E. CRISPR-based subtyping to track the evolutionary history of a global clone of Acinetobacter baumannii. Infect. Genet. Evol. 2021, 90, 104774. [CrossRef]
17. Higgins, P.G.; Hagen, R.M.; Kreikemeyer, B.; Warnke, P.; Podbielski, A.; Frickmann, H.; Loderstädt, U. Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii Isolates from Northern Africa and the Middle East. Antibiotics 2021, 10, 291. [CrossRef] [PubMed]
18. Frickmann, H.; Essig, A.; Hagen, R.M.; Riecker, M.; Jerke, K.; Ellison, D.; Poppert, S. Rapid identification of Acinetobacter spp. by fluorescence in situ hybridization (FISH) from colony and blood culture material. Eur. J. Microbiol. Immunol. 2011, 1, 289–296. [CrossRef]
19. Higgins, P.G.; Hagen, R.M.; Kreikemeyer, B.; Warnke, P.; Podbielski, A.; Frickmann, H.; Loderstädt, U. Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii and Acinetobacter genomic species 13TU isolates using a multilocus sequencing typing scheme. Clin. Microbiol. Infect. 2008, 14, 708–715. [CrossRef]
20. Diancourt, L.; Passet, V.; Nemec, A.; Dijkshoorn, L.; Brisse, S. The population structure of Acinetobacter baumannii: Expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS ONE 2010, 5, e10034. [CrossRef]
21. Cerezales, M.; Biniossek, L.; Gerson, S.; Xanthopoulou, K.; Wille, J.; Wohlfarth, E.; Kaase, M.; Seifert, H.; Higgins, P.G. Novel multiplex PCRs for detection of the most prevalent carbapenemase genes in Gram-negative bacteria within Germany. J. Med. Microbiol. 2021, 70, 3. [CrossRef] [PubMed]
22. Higgins, P.G.; Hagen, R.M.; Podbielski, A.; Frickmann, H.; Warnke, P. Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii Isolated from War-Injured Patients from the Eastern Ukraine. Antibiotics 2020, 9, 579. [CrossRef] [PubMed]
23. Kleinheinz, K.A.; Joensen, K.G.; Larsen, M.V. Applying the ResFinder and VirulenceFinder web-services for easy identification of acquired antibiotic resistance and E. coli virulence genes in bacteriophage and prophage nucleotide sequences. Bacteriophage 2014, 4, e27943. [CrossRef] [PubMed]
24. Frickmann, H.; Podbielski, A.; Kreikemeyer, B. Resistant Gram-Negative Bacteria and Diagnostic Point-of-Care Options for the Field Setting during Military Operations. Biomed. Res. Int. 2018, 2018, 9395420. [CrossRef] [PubMed]